[go: up one dir, main page]

FI945553L - Peptidien suoloja karboksipäätteisten polyestereiden kanssa - Google Patents

Peptidien suoloja karboksipäätteisten polyestereiden kanssa Download PDF

Info

Publication number
FI945553L
FI945553L FI945553A FI945553A FI945553L FI 945553 L FI945553 L FI 945553L FI 945553 A FI945553 A FI 945553A FI 945553 A FI945553 A FI 945553A FI 945553 L FI945553 L FI 945553L
Authority
FI
Finland
Prior art keywords
carboxy
peptides
salts
terminated polyesters
polyesters
Prior art date
Application number
FI945553A
Other languages
English (en)
Swedish (sv)
Other versions
FI112603B (fi
FI945553A0 (fi
Inventor
Francis Gowland Hutchinson
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of FI945553A0 publication Critical patent/FI945553A0/fi
Publication of FI945553L publication Critical patent/FI945553L/fi
Application granted granted Critical
Publication of FI112603B publication Critical patent/FI112603B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
FI945553A 1992-05-28 1994-11-25 Menetelmä peptidikationin ja polyesterianionin käsittävän koostumuksen valmistamiseksi FI112603B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB@@@@A GB9211268D0 (en) 1992-05-28 1992-05-28 Salts of basic peptides with carboxyterminated polyesters
PCT/GB1993/001079 WO1993024150A1 (en) 1992-05-28 1993-05-25 Salts of peptides with carboxy-terminated polyesters

Publications (3)

Publication Number Publication Date
FI945553A0 FI945553A0 (fi) 1994-11-25
FI945553L true FI945553L (fi) 1995-01-25
FI112603B FI112603B (fi) 2003-12-31

Family

ID=10716132

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945553A FI112603B (fi) 1992-05-28 1994-11-25 Menetelmä peptidikationin ja polyesterianionin käsittävän koostumuksen valmistamiseksi

Country Status (33)

Country Link
US (3) US5889110A (fi)
JP (1) JPH08501064A (fi)
KR (1) KR100293882B1 (fi)
AT (1) AT407702B (fi)
AU (1) AU682310B2 (fi)
BE (1) BE1006143A3 (fi)
CA (1) CA2136751C (fi)
CH (2) CH688911A5 (fi)
CZ (1) CZ292449B6 (fi)
DE (2) DE4392401B4 (fi)
DK (1) DK176134B1 (fi)
ES (1) ES2107357B1 (fi)
FI (1) FI112603B (fi)
FR (1) FR2691631B1 (fi)
GB (3) GB9211268D0 (fi)
GR (1) GR1001550B (fi)
HK (1) HK133097A (fi)
HU (1) HUT70177A (fi)
IE (1) IE74715B1 (fi)
IL (1) IL105710A (fi)
IT (1) IT1271139B (fi)
LU (1) LU88559A1 (fi)
MC (1) MC2330A1 (fi)
NL (1) NL195056C (fi)
NO (1) NO311006B1 (fi)
NZ (1) NZ252268A (fi)
RU (1) RU2152225C1 (fi)
SE (1) SE501970C2 (fi)
SG (1) SG44645A1 (fi)
SK (1) SK280320B6 (fi)
TW (1) TW223018B (fi)
WO (1) WO1993024150A1 (fi)
ZA (1) ZA933358B (fi)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP0949905B1 (en) * 1996-12-20 2001-07-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040142475A1 (en) * 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents
AU9489801A (en) * 2000-09-28 2002-04-08 Chiron Corp Microparticle compositions and methods for the manufacture thereof
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
CA2460867C (en) * 2001-09-19 2011-04-12 Elan Pharma International Ltd. Nanoparticulate insulin formulations
PL211116B1 (pl) * 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
MXPA04004665A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
NZ533435A (en) * 2001-11-14 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
ATE374598T1 (de) * 2002-03-15 2007-10-15 Alrise Biosystems Gmbh Mikropartikel und verfahren zur deren herstellung
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
DK1532985T3 (en) 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AU2003256849A1 (en) * 2002-07-31 2004-02-16 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
NZ537955A (en) * 2002-07-31 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
KR101268258B1 (ko) 2002-09-06 2013-05-31 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
WO2004043432A2 (en) 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
PT2246360E (pt) 2003-01-28 2012-08-31 Ironwood Pharmaceuticals Inc Composições para o tratamento de desordens gastrointestinais
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7741268B2 (en) * 2003-04-02 2010-06-22 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
EP1660013A4 (en) 2003-08-26 2011-07-20 Gel Del Technologies Inc BIOMATERIAL AND PROTEIN BIOCOACERVATES, METHODS OF MAKING AND USING THEM
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
DK1682537T3 (da) 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
AU2004296851A1 (en) 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
PL1881823T3 (pl) 2005-05-17 2015-05-29 Sarcode Bioscience Inc Kompozycje i sposoby leczenia chorób oczu
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
RU2327459C1 (ru) * 2007-06-26 2008-06-27 Евгений Сергеевич Северин Лекарственное средство противомикробного действия, способ получения лекарственного препарата направленного действия, содержащего наночастицы
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
US20090163603A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
CA2711001A1 (en) 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein-based particles and methods thereof
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US10016534B2 (en) 2008-11-17 2018-07-10 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20110160159A1 (en) 2009-09-15 2011-06-30 John Ryan Treatment of cancer
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
KR20120098906A (ko) * 2009-12-22 2012-09-05 다케다 야쿠힌 고교 가부시키가이샤 서방성 제제
DE102010003615A1 (de) * 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
PH12012502548A1 (en) * 2010-06-25 2013-02-11 Takeda Pharmaceuticals Co Sustained-release formulation
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012151343A1 (en) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
KR101467275B1 (ko) * 2011-12-19 2014-12-02 주식회사 삼양바이오팜 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
EP3715345B8 (en) 2012-07-25 2024-05-29 Bausch + Lomb Ireland Limited Preparation of lfa-1 inhibitor
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US10695295B2 (en) * 2013-03-04 2020-06-30 Besins Healthcare Luxembourg Sarl Spray-dried pharmaceutical compositions comprising active agent nanoparticles
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
SMT202500100T1 (it) 2016-04-12 2025-05-12 Tonix Pharma Ltd Formulazioni di ossitocina contenenti magnesio e metodi d'uso
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN110954491B (zh) * 2019-12-09 2022-11-15 北京博恩特药业有限公司 用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
US20250009647A1 (en) 2021-08-05 2025-01-09 Medincell S.A. Pharmaceutical composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5005602A (en) * 1985-12-24 1991-04-09 Dover Corporation Poppet valve assembly
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CH679207A5 (fi) * 1989-07-28 1992-01-15 Debiopharm Sa
EP0489743A1 (en) * 1990-07-03 1992-06-17 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IL96129A0 (en) * 1990-07-20 1991-07-18 Spectronix Ltd Method and apparatus for detecting a fire,explosion,or projectile-penetration in a monitored space
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Also Published As

Publication number Publication date
CH688911A5 (de) 1998-05-29
HK133097A (en) 1997-10-24
HU9403371D0 (en) 1995-02-28
NL195056C (nl) 2003-07-01
CZ292449B6 (cs) 2003-09-17
SE501970C2 (sv) 1995-07-03
FI112603B (fi) 2003-12-31
GB9309645D0 (en) 1993-06-23
MC2330A1 (fr) 1994-05-31
AU4084793A (en) 1993-12-30
DE4392401B4 (de) 2007-05-16
DK135394A (da) 1994-11-28
HUT70177A (en) 1995-09-28
IE74715B1 (en) 1997-07-30
DK176134B1 (da) 2006-09-18
US5889110A (en) 1999-03-30
RU2152225C1 (ru) 2000-07-10
NO311006B1 (no) 2001-10-01
ES2107357B1 (es) 1998-10-16
GB9211268D0 (en) 1992-07-15
IT1271139B (it) 1997-05-27
WO1993024150A1 (en) 1993-12-09
CZ293794A3 (en) 1995-03-15
NO944535D0 (no) 1994-11-25
SK143494A3 (en) 1995-07-11
ITMI931099A1 (it) 1994-11-27
BE1006143A3 (fr) 1994-05-24
SE9404115L (sv) 1994-11-28
ZA933358B (en) 1994-09-15
CA2136751A1 (en) 1993-12-09
GB2282066A (en) 1995-03-29
IL105710A (en) 2001-03-19
US20020198315A1 (en) 2002-12-26
SG44645A1 (en) 1997-12-19
LU88559A1 (fr) 1995-04-05
IL105710A0 (en) 1993-09-22
NO944535L (no) 1995-01-25
GB2282066B (en) 1996-11-06
GR1001550B (el) 1994-04-29
JPH08501064A (ja) 1996-02-06
TW223018B (en) 1994-05-01
KR100293882B1 (ko) 2001-09-17
FR2691631B1 (fr) 1995-06-09
ITMI931099A0 (it) 1993-05-27
ATA901993A (de) 2000-10-15
US6034175A (en) 2000-03-07
CA2136751C (en) 2006-10-31
GB9423366D0 (en) 1995-01-25
IE930358A1 (en) 1993-12-01
DE4392401T1 (de) 1997-07-24
AU682310B2 (en) 1997-10-02
FR2691631A1 (fr) 1993-12-03
ES2107357A1 (es) 1997-11-16
NZ252268A (en) 1996-12-20
NL9320034A (nl) 1995-04-03
SK280320B6 (sk) 1999-11-08
RU94046097A (ru) 1996-09-20
SE9404115D0 (sv) 1994-11-28
FI945553A0 (fi) 1994-11-25
AT407702B (de) 2001-05-25
CH690491A5 (de) 2000-09-29

Similar Documents

Publication Publication Date Title
FI945553L (fi) Peptidien suoloja karboksipäätteisten polyestereiden kanssa
AT399790B (de) Hochspannungswicklung
FI940642L (fi) Imidatsolyyli-alkeenihapot
FI923058L (fi) Esterifieringsfoerfarande
DE69333329D1 (de) Polyesterfolie
DE69220382D1 (de) Verwendung von Peptidderivaten
DK223390D0 (da) Modificerede hydrofile polyestere
FI944802L (fi) HLE-proteiinien aktiivisuutta inhiboivat laktaamidipeptidit
FI924570A7 (fi) Bentsimidatsolifosfonoaminohappoja
FI932427A7 (fi) Syklopentaani- ja -penteeni-b-aminohapot
DE59305938D1 (de) Pyridyloxy-acrylsäureester
DE59205221D1 (de) 1-Alkoxyhexatrien-2-carbonsäureester
ATE125794T1 (de) Prodrogen von antiinflammatorischen 3-acyl-2- oxindol-1-carboxamiden.
FI933300L (fi) Foerfarande foer rengoering av klorvaetesyra i gasform
FI934222A7 (fi) Pyridatsinonietikkahappoja
DE69312093D1 (de) Prodrug von entzündungshemmenden 3-acyl-2-oxindol-1-carboxamiden
DE69327014D1 (de) Polyesterfolie
DE69322550D1 (de) Polyesterfilm
FI932510A7 (fi) Uudet tiosemikarbatsonihappoesterit
DE69215932D1 (de) Ester von Pregna-21-säure
NO920022D0 (no) Umettede hydroksyalkylkinolinsyrer
SK200U (sk) Mechanický pohon skladovacieho systému
SE9202754D0 (sv) Fulfilment
KR930022855U (ko) 칫솔의 인식 표시장치
ITMI910513A1 (it) Nuovi acidi indazolici